Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Mutations in the SLC34A3 gene disrupt the NaPi-IIc transporter in the kidney's proximal tubule, causing phosphate to leak into the urine instead of being reabsorbed, a condition known as hereditary hypophosphatemic rickets with hypercalciuria (HHRH). The resulting low blood phosphate triggers excess active vitamin D, which drives up calcium absorption and floods the urine with calcium, setting the stage for calcium-based kidney stones, nephrocalcinosis, bone pain, and rickets or osteomalacia. Carriers with a single variant may still show high urine calcium and stones without obvious bone disease, and treatment differs sharply from other phosphate-wasting disorders because standard vitamin D therapy can worsen stone formation. There are several important genetic, lab, and treatment details to weigh, so see below to understand more.
If recurring stones, unexplained bone pain, or a family history of kidney stones sounds familiar, a free, instant, online symptom check can help you organize your symptoms and see which possible causes and next steps deserve attention before your next appointment.
Last reviewed for medical accuracy: 08/18/2026
Understanding SLC34A3 Mutations: How Genetic Phosphate Leaks Cause Kidney Stones
Our kidneys filter and balance minerals every day. One key player is phosphate, essential for bone strength, muscle function and energy. The SLC34A3 gene makes a transporter (NPT2c) in kidney cells that reclaims phosphate from the urine back into the blood. When SLC34A3 is mutated, this transporter doesn’t work properly, leading to phosphate loss, bone problems and, paradoxically, kidney stones.
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is the classic condition caused by SLC34A3 mutations. Despite the name, many people present with kidney stones rather than rickets. Key features include:
• Bone pain or fractures from weakened bones
• Muscle weakness or cramps
• Growth delay in children
• Frequent kidney stones or nephrocalcinosis (calcium deposits in kidneys)
• Normal or elevated blood calcium levels (due to increased calcitriol)
• High urinary phosphate and calcium
Symptoms vary by age and mutation severity. Common signs:
• Recurrent kidney stones (often starting in adolescence or adulthood)
• Bone pain in legs or hips
• Dental issues (enamel defects, cavities)
• Short stature or bowed legs in children
• Fatigue, muscle cramps
Some people have only mild bone changes but significant stone disease. If you or a family member has unexplained stones alongside low phosphate levels, HHRH should be considered.
A thorough workup includes:
Blood tests
Urine tests
Genetic testing
Imaging
Treatment goals are to restore phosphate balance, protect bones and prevent stones:
• Oral phosphate supplements
– Replenish lost phosphate
– Improve bone mineralization
– Dosed multiple times daily with meals
• Active vitamin D analogs
– Calcitriol or alfacalcidol can normalize vitamin D metabolism
– Used carefully to avoid worsening hypercalciuria
• Hydration
– Drink plenty of water to dilute urine and reduce stone risk
– Aim for at least 2–3 liters daily, unless fluid restriction is needed for other reasons
• Dietary adjustments
– Moderate dietary calcium (avoid excessive intake)
– Limit high-oxalate foods (e.g., spinach, nuts) if calcium-oxalate stones are a problem
– Maintain balanced sodium intake, as high salt increases calcium excretion
• Monitoring
– Regular blood and urine tests every 3–6 months initially
– Periodic imaging to watch for stones or nephrocalcinosis
Close follow-up with a nephrologist or metabolic bone specialist helps fine-tune doses and avoid side effects, such as over-suppression of PTH or excessive urinary calcium.
Untreated HHRH can lead to:
• Recurrent, painful kidney stones
• Chronic kidney disease from stone damage or nephrocalcinosis
• Height and growth problems in children
• Bone deformities and fractures
• Dental issues
Timely diagnosis and tailored treatment minimize these risks.
Consider evaluation if you have:
• Multiple kidney stones without clear cause
• Low serum phosphate on routine labs
• Family history of stones or bone disease
• Unexplained bone pain, fractures or rickets in childhood
• Persistent hypercalciuria despite dietary measures
A free, online symptom check, using the doctor approved Ubie Symptom Checker can help you identify whether these symptoms fit HHRH or other conditions. Speak directly with a healthcare provider if any red-flag signs arise.
Because HHRH is autosomal recessive:
• Each child of two carriers has a 25% chance of being affected.
• Siblings of an affected individual have a 2 in 3 chance of being carriers.
• Genetic counseling helps families understand inheritance, testing options and implications for future children.
Always seek medical advice if you experience:
• Severe, unrelenting kidney stone pain
• Blood in the urine
• Signs of kidney infection (fever, chills, back pain)
• Any sudden decrease in urine output
• Bone pain that interferes with daily activities
These could signal serious complications requiring prompt attention.
Living with HHRH means partnering closely with healthcare professionals. Regular monitoring, the right supplements and lifestyle tweaks allow most people to lead full, active lives. Advances in genetic research and new therapies continue to improve outcomes.
This overview equips you with the basics of SLC34A3 mutations and their link to phosphate leaks, kidney stones and hereditary hypophosphatemic rickets with hypercalciuria. For tailored advice, always speak to your doctor or a genetic specialist, especially if you suspect a serious or potentially life-threatening issue. If you’re unsure about your symptoms, try a free, online symptom check, using the doctor approved Ubie Symptom Checker to guide your next steps.
(References)
* Kronenberg HM. NPT2a--the key to phosphate homeostasis. N Engl J Med. 2002 Sep 26;347(13):1022-4. doi: 10.1056/NEJMe020098. PMID: 12324560.
* Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, Schlingmann KP, Janner M, Biggin A, Lazier J, Gessner M, Chrysis D, Tuchman S, Baluarte HJ, Levine MA, Tiosano D, Insogna K, Hanley DA, Carpenter TO, Ichikawa S, Hoppe B, Konrad M, Sävendahl L, Munns CF, Lee H, Jüppner H, Bergwitz C. Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol. 2014 Oct;25(10):2366-75. doi: 10.1681/ASN.2013101085. Epub 2014 Apr 3. PMID: 24700880; PMCID: PMC4178443.
* Tabibzadeh N, Cheddani L, Daudon M, Haymann JP, Toussaint A, Silve C, Letavernier E. The Case | Epistasis and urolithiasis. Kidney Int. 2017 Aug;92(2):523-524. doi: 10.1016/j.kint.2017.01.026. PMID: 28709611.
* Hoppe B, Martin-Higueras C. Inherited conditions resulting in nephrolithiasis. Curr Opin Pediatr. 2020 Apr;32(2):273-283. doi: 10.1097/MOP.0000000000000848. PMID: 31789978.
* Cogal AG, Arroyo J, Shah RJ, Reese KJ, Walton BN, Reynolds LM, Kennedy GN, Seide BM, Senum SR, Baum M, Erickson SB, Jagadeesh S, Soliman NA, Goldfarb DS, Beara-Lasic L, Edvardsson VO, Palsson R, Milliner DS, Sas DJ, Lieske JC, Harris PC, Investigators of the Rare Kidney Stone Consortium. Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. Kidney Int Rep. 2021 Nov;6(11):2862-2884. doi: 10.1016/j.ekir.2021.08.033. Epub 2021 Sep 8. PMID: 34805638; PMCID: PMC8589729.
* Gefen AM, Sethna CB, Cil O, Perwad F, Schoettler M, Michael M, Angelo JR, Safdar A, Amlie-Wolf L, Hunley TE, Ellison JS, Feig D, Zaritsky J. Genetic testing in children with nephrolithiasis and nephrocalcinosis. Pediatr Nephrol. 2023 Aug;38(8):2615-2622. doi: 10.1007/s00467-023-05879-0. Epub 2023 Jan 23. PMID: 36688940; PMCID: PMC11071637.
* Nwachukwu C, Singh G, Moore B, Strande NT, Bucaloiu ID, Chang AR. Risk of Nephrolithiasis in Adults Heterozygous for SLC34A3 Ser192Leu in an Unselected Health System Cohort. J Am Soc Nephrol. 2023 Nov 1;34(11):1819-1821. doi: 10.1681/ASN.0000000000000204. Epub 2023 Aug 28. PMID: 37639356; PMCID: PMC10631595.
* Wagner CA, Egli-Spichtig D, Rubio-Aliaga I. Updates on renal phosphate transport. Curr Opin Nephrol Hypertens. 2025 Jul 1;34(4):269-275. doi: 10.1097/MNH.0000000000001090. Epub 2025 May 13. PMID: 40357590; PMCID: PMC12144537.
* Lovegrove CE, Goldsworthy M, Haley J, Smelser D, Gorvin C, Hannan FM, Mahajan A, Suri M, Sadeghi-Alavijeh O, Moochhala SH, Gale DP, Carey D, Holmes MV, Furniss D, Thakker RV, Howles SA. Genetic variants predisposing to an increased risk of kidney stone disease. J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI186915. Epub 2025 May 15. PMID: 40372791; PMCID: PMC12321396.
* Li S, Wang X, Liu M. Genetic susceptibility to kidney stone disease: unveiling pathogenesis and potential therapeutic targets. J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI195624. Epub 2025 Aug 1. PMID: 40759569; PMCID: PMC12321377.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.